Nivolumab + Ipilimumab + Carboplatin + Cisplatin + Gemcitabine + Pemetrexed + Paclitaxel
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Aug 5, 2015 → Oct 25, 2024
NCT ID
NCT02477826About Nivolumab + Ipilimumab + Carboplatin + Cisplatin + Gemcitabine + Pemetrexed + Paclitaxel
Nivolumab + Ipilimumab + Carboplatin + Cisplatin + Gemcitabine + Pemetrexed + Paclitaxel is a phase 3 stage product being developed by Ono Pharmaceutical for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02477826. Target conditions include Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02477826 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer